NCI-COG Pediatric MATCH
This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. See study details page. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. See the table below for open treatment arms.
https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/pediatric-match#1
For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Email: cancer@cchmc.org
|
TARGET |
STUDY / ID |
AGENT |
KEY WORDS |
DATE MODIFIED |
STATUS |
|
NA |
SC |
N/A |
Screening Protocol |
12/19/2022 |
OPEN |
|
Pan-TRK inhibitor |
A |
LOXO-101 (larotrectinib) |
NTRK Fusions |
12/19/2022 |
OPEN |
|
P13K/mTOR inhibitor |
D |
LY3023414 |
Solid tumors |
12/19/2022 |
OPEN |
|
ALK or ROS1 alterations |
F |
Ensartinib |
ALK alterations, ROS1 alterations |
12/23/2022 |
OPEN |
|
IDH1 Mutations |
K |
Ivosidenib |
IDH1 Mutations |
12/19/2022 |
OPEN |
|
HRAS genomic |
M |
Tipifarnib |
HRAS genomic alterations |
12/19/2022 |
OPEN |
|
RET Gene Alterations |
N |
LOXO-292 |
RET Gene Alterations |
12/19/2022 |
OPEN |
